Summary

The Point of Care Diagnostics market is projected to reach USD 31.46 billion by 2031 from USD 20.63 billion in 2026, growing at a CAGR of 8.8%.

Continuous technological advancements and the growing demand for rapid, accurate, and decentralized testing are driving growth in the point-of-care diagnostics market. Biochemistry technology accounts for the largest market share due to its widespread use in blood glucose monitoring, blood gas and electrolyte analysis, cholesterol testing, and other routine diagnostic applications across hospitals, clinical laboratories, emergency departments, and physician offices. Its broad clinical utility, cost-effectiveness, and ability to deliver rapid results make it the preferred technology for high-volume point-of-care testing. Meanwhile, molecular diagnostics is projected to grow the fastest, owing to the increasing adoption of rapid PCR-based platforms for infectious disease detection, antimicrobial resistance testing, and outbreak preparedness. Continuous innovations in immunoassays, molecular platforms, microfluidics, multiplex testing, and portable analyzers are improving diagnostic accuracy, reducing turnaround time, and expanding testing beyond traditional laboratories. These advancements are accelerating the adoption of next-generation point-of-care diagnostic technologies across hospitals, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings, thereby creating sustained global demand for advanced diagnostic solutions.

Based on product: Infectious disease testing products are projected to register the highest growth during the forecast period. The segment's dominance is driven by the increasing burden of infectious diseases, the growing demand for rapid, accurate near-patient diagnosis, and the need for timely clinical decision-making to support effective treatment and infection control. The growing adoption of point-of-care testing across hospitals, emergency departments, physicians' offices, retail clinics, pharmacies, and home healthcare settings, coupled with expanding government initiatives for infectious disease surveillance and decentralized healthcare delivery, continues to strengthen the market position of infectious disease testing products.

Based on end user: Clinical laboratories account for the largest share of the point-of-care diagnostics market due to their central role in delivering rapid and accurate diagnostic testing for both acute and chronic diseases. These facilities routinely perform point-of-care testing for infectious diseases, diabetes, cardiovascular disorders, coagulation monitoring, and clinical chemistry, supporting timely diagnosis and treatment decisions. Their extensive testing capabilities, skilled laboratory personnel, established quality management systems, and seamless integration with hospital workflows continue to drive demand for point-of-care diagnostic solutions. Furthermore, increasing test volumes, the growing emphasis on faster turnaround times, and the expanding adoption of decentralized testing within laboratory networks reinforce the dominance of clinical laboratories in the global point-of-care diagnostics market.

North America accounts for the largest share of the point-of-care diagnostics market due to its advanced healthcare infrastructure, strong reimbursement framework, and widespread adoption of decentralized diagnostic testing. The region has an extensive network of hospitals, clinical laboratories, physicians' offices, urgent care centers, retail clinics, and pharmacies that routinely use point-of-care diagnostics to rapidly detect and manage infectious diseases, diabetes, cardiovascular disorders, and respiratory conditions. High healthcare expenditure, a strong presence of leading diagnostic manufacturers, and favorable regulatory support have accelerated the adoption of point-of-care testing across the U.S. and Canada. Furthermore, increasing emphasis on early diagnosis, improved patient outcomes, and reducing healthcare costs through near-patient testing continues to reinforce North America's leadership in the global point-of-care diagnostics market.
A breakdown of the primary respondents (supply-side) for the POC diagnostics s market referred to in this report is provided below:
・ By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
・ By Designation: C-level: 55%, Director Level: 27%, and Others: 18%
・ By Region: North America: 43%, Europe: 28%, Asia Pacific: 20%, Latin America: 6%, and Middle East & Africa: 3%
Prominent players in the global point-of-care diagnostics market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), bioMérieux SA (France), Werfen S.A. (Spain), Becton, Dickinson and Company (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), OraSure Technologies, Inc. (US), EKE Diagnostics (China), Trinity Biotech plc (Ireland), Grifols S.A. (Spain), Nova Biomedical Corporation (US), Sekisui Diagnostics, LLC (US), Trividia Health, Inc. (US), Sysmex Corporation (Japan), HemoCue AB (Sweden), and Bio-Rad Laboratories, Inc. (US) among others.
Research Coverage
The report evaluates the POC diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will assist market leaders and new entrants in the POC diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the POC diagnostics market.
This report provides insights into the following points:
・Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases requiring rapid diagnosis, growing demand for decentralized and near-patient testing to enable faster clinical decision-making, increasing adoption of portable and user-friendly diagnostic devices in hospitals, clinics, and home care settings, technological advancements in microfluidics, biosensors, AI-enabled diagnostics, and smartphone-integrated testing solutions), restraints (high cost of advanced point-of-care diagnostic devices and consumables, stringent regulatory approval and quality compliance requirements, limited accuracy of certain rapid tests compared to centralized laboratory testing, data security and interoperability concerns with connected diagnostic systems), opportunities (expansion of point-of-care testing in emerging markets, increasing demand for home-based diagnostic kits and self-testing solutions, growing adoption of multiplex and molecular point-of-care diagnostics, rising investments in digital health, telemedicine, and AI-powered diagnostic platforms), and challenges (limited healthcare infrastructure and trained personnel in low-resource settings, reimbursement and pricing pressures, supply chain constraints for diagnostic reagents and consumables, standardization and integration of point-of-care diagnostic data with electronic health record systems)
・Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global POC diagnostics market.
・Market Development: Thorough knowledge and analysis of the profitable rising markets by product, sample, mode of purchase, technology, end user, and region.
・Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global POC diagnostics market.
・Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global POC diagnostics market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.3 STUDY SCOPE 49
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 49
1.3.2 INCLUSIONS AND EXCLUSIONS 50
1.3.3 YEARS CONSIDERED 51
1.3.4 CURRENCY CONSIDERED 52
1.4 STAKEHOLDERS 52
1.5 SUMMARY OF CHANGES 52
2 EXECUTIVE SUMMARY 54
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 54
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 55
2.3 DISRUPTIVE TRENDS SHAPING MARKET 56
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 57
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 58
3 PREMIUM INSIGHTS 60
3.1 POC DIAGNOSTICS MARKET OVERVIEW 60
3.2 POC DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031 61
3.3 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2026 VS. 2031 61
3.4 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 62
3.5 POC DIAGNOSTICS MARKET, BY SAMPLE, 2026 VS. 2031 62
3.6 POC DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031 63
3.7 POC DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
4 MARKET OVERVIEW 64
4.1 INTRODUCTION 64
4.2 MARKET DYNAMICS 64
4.2.1 DRIVERS 65
4.2.1.1 Growing incidence of infectious diseases 65
4.2.1.2 Increasing prevalence of chronic diseases 67
4.2.1.3 Favorable government initiatives for POC testing 68
4.2.1.4 Rising number of waived tests 69
4.2.2 RESTRAINTS 70
4.2.2.1 Pricing pressure on manufacturers 70
4.2.2.2 Stringent regulatory approval process for product commercialization 71
4.2.3 OPPORTUNITIES 71
4.2.3.1 Increasing growth potential in emerging markets 71
4.2.3.2 Rising inclination toward decentralized healthcare systems 72
4.2.3.3 Booming healthcare spending worldwide 72
4.2.4 CHALLENGES 73
4.2.4.1 Inadequate standardization with centralized lab methods 73
4.2.4.2 Premium pricing of novel platforms 74
4.3 UNMET NEEDS AND WHITE SPACES 74
4.3.1 UNMET NEEDS IN POC DIAGNOSTICS MARKET 74
4.3.2 WHITE SPACE OPPORTUNITIES 75
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 76
4.4.1 INTERCONNECTED MARKETS 76
4.4.2 CROSS-SECTOR OPPORTUNITIES 78
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 79
4.5.1 KEY MOVES AND STRATEGIC FOCUS 79
5 INDUSTRY TRENDS 80
5.1 PORTER’S FIVE FORCES ANALYSIS 80
5.1.1 BARGAINING POWER OF SUPPLIERS 81
5.1.2 BARGAINING POWER OF BUYERS 81
5.1.3 THREAT OF NEW ENTRANTS 81
5.1.4 THREAT OF SUBSTITUTES 81
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 81
5.2 MACROECONOMIC INDICATORS 82
5.2.1 INTRODUCTION 82
5.2.2 GDP TRENDS AND FORECAST 82
5.3 SUPPLY CHAIN ANALYSIS 85
5.4 ECOSYSTEM ANALYSIS 86
5.5 INVESTMENT AND FUNDING SCENARIO 88
5.6 PRICING ANALYSIS 89
5.6.1 AVERAGE SELLING PRICE, BY PRODUCT 89
5.6.1.1 Average selling price OF glucose monitoring test strips, by key player 90
5.6.2 AVERAGE SELLING PRICE, BY REGION 90
5.6.2.1 Average selling price of glucose monitoring test strips, by region 90
5.6.2.2 Average selling price of infectious disease testing products, by region 91
5.6.2.3 Average selling price of cardiometabolic monitoring products,
by region 92
5.7 VALUE CHAIN ANALYSIS 93
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
5.9 IMPACT OF US TARIFFS—POC DIAGNOSTICS MARKET 95
5.9.1 INTRODUCTION 95
5.9.2 KEY TARIFF RATES 96
5.9.3 PRICE IMPACT ANALYSIS 96
5.9.4 IMPACT ON COUNTRIES/REGIONS 97
5.9.4.1 North America 97
5.9.4.2 Europe 97
5.9.4.3 Asia Pacific 97
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 98
6.1 KEY EMERGING TECHNOLOGIES 98
6.1.1 IMMUNOASSAYS 98
6.2 COMPLEMENTARY TECHNOLOGIES 98
6.2.1 MOLECULAR DIAGNOSTICS 98
6.3 ADJACENT TECHNOLOGIES 99
6.3.1 BIOCHEMICAL TECHNOLOGIES 99
6.4 TECHNOLOGY/PRODUCT ROADMAP 100
6.5 PATENT ANALYSIS 101
6.5.1 LIST OF MAJOR PATENTS 102
6.6 FUTURE APPLICATIONS 102
6.7 IMPACT OF AI/GENERATIVE AI ON POC DIAGNOSTICS MARKET 103
6.7.1 INTRODUCTION 103
6.7.2 TOP USE CASES AND MARKET POTENTIAL 104
6.7.3 KEY COMPANIES IMPLEMENTING AI 104
6.7.4 FUTURE OF AI 106
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 107
7.1 REGIONAL REGULATIONS AND COMPLIANCE 107
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
7.1.2 INDUSTRY STANDARDS 109
7.2 SUSTAINABILITY INITIATIVES 111
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN POC DIAGNOSTICS 111
7.2.1.1 Eco-friendly Initiatives 111
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 112
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113
8.1 DECISION-MAKING PROCESS 113
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 113
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113
8.2.2 BUYING CRITERIA 114
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 115
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116
8.5 MARKET PROFITABILITY 117
8.5.1 REVENUE POTENTIAL 117
8.5.2 COST DYNAMICS 117
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 118
9 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY 119
9.1 INTRODUCTION 120
9.2 BIOCHEMISTRY 120
9.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH 120
9.3 IMMUNOASSAYS 123
9.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET 123
9.4 MOLECULAR DIAGNOSTICS 127
9.4.1 RT-PCR 130
9.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market 130
9.4.2 INAAT 132
9.4.2.1 Emerging new pathogens to facilitate growth 132
10 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE 135
10.1 INTRODUCTION 136
10.2 BLOOD SAMPLES 136
10.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET 136
10.3 NASAL & OROPHARYNGEAL SWABS 140
10.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH 140
10.4 URINE SAMPLES 143
10.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET 143
10.5 OTHER SAMPLES 146
11 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 150
11.1 INTRODUCTION 151
11.2 PRESCRIPTION-BASED TESTING PRODUCTS 151
11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH 151
11.3 OTC TESTING PRODUCTS 155
11.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET 155
12 POINT OF CARE DIAGNOSTICS MARKET, BY END USER 159
12.1 INTRODUCTION 160
12.2 CLINICAL LABORATORIES 160
12.2.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET 160
12.3 HOME CARE SETTINGS & SELF-TESTING 163
12.3.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH 163
12.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS 165
12.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH 165
12.5 AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES 168
12.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH 168
12.6 OTHER END USERS 171
13 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT 174
13.1 INTRODUCTION 175
13.2 GLUCOSE MONITORING PRODUCTS 176
13.2.1 GLUCOSE MONITORING STRIPS 178
13.2.1.1 Growing trend toward preventive healthcare to drive market 178
13.2.2 GLUCOSE MONITORING METERS 181
13.2.2.1 Growing technological advancements in glucose meters to propel market 181
13.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES 184
13.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth 184
13.3 CARDIOMETABOLIC TESTING PRODUCTS 186
13.3.1 CARDIAC MARKER TESTING PRODUCTS 190
13.3.1.1 Growing government support for cardiovascular diseases to drive market 190
13.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 192
13.3.2.1 Need to optimize hospital workflow to favor growth 192
13.3.3 HBA1C TESTING PRODUCTS 195
13.3.3.1 Increasing recommendations by government healthcare authorities to boost market 195
13.4 INFECTIOUS DISEASE TESTING PRODUCTS 197
13.4.1 RESPIRATORY INFECTION TESTING PRODUCTS 200
13.4.1.1 Influenza testing products 203
13.4.1.1.1 Need for targeted treatments to expedite growth 203
13.4.1.2 Tuberculosis testing products 206
13.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth 206
13.4.1.3 Other respiratory infection testing products 208
13.4.2 HAI TESTING PRODUCTS 211
13.4.2.1 Growing rate of surgical-site infections to boost market 211
13.4.3 TROPICAL DISEASE TESTING PRODUCTS 214
13.4.3.1 Rising incidence of malaria and dengue to support growth 214
13.4.4 STD TESTING PRODUCTS 216
13.4.4.1 HIV testing products 219
13.4.4.1.1 Growing availability and awareness of testing products to boost market 219
13.4.4.2 Hepatitis testing products 222
13.4.4.2.1 Hepatitis B testing products 224
13.4.4.2.1.1 Increasing prevalence of liver infections to favor growth 224
13.4.4.2.2 Hepatitis C testing products 227
13.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth 227
13.4.4.3 Syphilis testing products 229
13.4.4.3.1 Need for early and accessible diagnosis to expedite growth 229
13.4.4.4 Human papillomavirus testing products 232
13.4.4.4.1 Rising cases of cervical cancer to promote growth 232
13.4.4.5 Chlamydia trachomatis testing products 235
13.4.4.5.1 Growing adoption of advanced techniques to drive market 235
13.4.4.6 Neisseria gonorrhea testing products 238
13.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth 238
13.4.4.7 HSV testing products 240
13.4.4.7.1 Increasing incidence of herpes to support growth 240
13.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS 243
13.4.5.1 Rising cases among hospitalized patients to boost demand 243
13.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 245
13.5 COAGULATION MONITORING PRODUCTS 248
13.5.1 NEED FOR REGULAR MONITORING AND RISING DEMAND FOR HOME-USE KITS TO PROPEL MARKET 248
13.5.2 PT/INR TESTING PRODUCTS 251
13.5.2.1 Increasing number of atrial fibrillation cases to accelerate growth 251
13.5.3 ACT/APTT TESTING PRODUCTS 253
13.5.3.1 Rise in surgical procedures to speed up growth 253
13.6 PREGNANCY & FERTILITY TESTING PRODUCTS 255
13.6.1 PREGNANCY TESTING PRODUCTS 257
13.6.1.1 Increasing awareness about family planning to stimulate growth 257
13.6.2 FERTILITY TESTING PRODUCTS 260
13.6.2.1 Growing infertility issues to fuel market 260
13.7 TUMOR/CANCER MARKER TESTING PRODUCTS 263
13.7.1 GROWING CANCER INCIDENCE AND GOVERNMENT SUPPORT FOR CANCER MANAGEMENT AND THERAPIES DRIVE MARKET 263
13.8 URINALYSIS TESTING PRODUCTS 266
13.8.1 INCREASING DEMAND FOR RAPID POC TESTING TECHNOLOGIES TO SUPPORT MARKET GROWTH 266
13.9 CHOLESTEROL TESTING PRODUCTS 269
13.9.1 GROWING GERIATRIC POPULATION AND RISING OBESITY LEVELS TO DRIVE MARKET 269
13.10 HEMATOLOGY TESTING PRODUCTS 272
13.10.1 RAPID DIAGNOSTICS AND MONITORING SUPPORT TO PROPEL END-USER ADOPTION 272
13.11 DRUGS-OF-ABUSE TESTING PRODUCTS 275
13.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET 275
13.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS 278
13.12.1 GROWING PREVALENCE OF THYROID DISORDERS DRIVING DEMAND FOR TSH TESTING PRODUCTS 278
13.13 FECAL OCCULT TESTING PRODUCTS 280
13.13.1 GROWING INCIDENCE OF CANCER TO PROPEL THE MARKET 280
13.14 OTHER PRODUCTS 283
14 POINT OF CARE DIAGNOSTICS MARKET, BY REGION 287
14.1 INTRODUCTION 288
14.2 NORTH AMERICA 288
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 289
14.2.2 US 296
14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditure to aid growth 296
14.2.3 CANADA 302
14.2.3.1 Rising incidence of diabetes and infectious diseases to support growth 302
14.3 EUROPE 308
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 309
14.3.2 GERMANY 316
14.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth 316
14.3.3 FRANCE 322
14.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market 322
14.3.4 UK 328
14.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth 328
14.3.5 ITALY 334
14.3.5.1 Growing burden of infectious and parasitic diseases to boost market 334
14.3.6 SPAIN 340
14.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth 340
14.3.7 REST OF EUROPE 346
14.4 ASIA PACIFIC 352
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 352
14.4.2 CHINA 359
14.4.2.1 Increasing impact of diabetes on public health to amplify growth 359
14.4.3 JAPAN 365
14.4.3.1 Booming geriatric population to stimulate growth 365
14.4.4 INDIA 371
14.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth 371
14.4.5 AUSTRALIA 378
14.4.5.1 Growing research investments for next-gen POC devices to boost market 378
14.4.6 SOUTH KOREA 384
14.4.6.1 Growing focus on innovative diagnostic products to drive market 384
14.4.7 REST OF ASIA PACIFIC 390
14.5 LATIN AMERICA 395
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 396
14.5.2 BRAZIL 402
14.5.2.1 Increasing public initiatives in healthcare to encourage growth 402
14.5.3 MEXICO 408
14.5.3.1 Need for frequent testing for disease management to expedite growth 408
14.5.4 REST OF LATIN AMERICA 414
14.6 MIDDLE EAST & AFRICA 420
14.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET 420
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 420
15 COMPETITIVE LANDSCAPE 426
15.1 INTRODUCTION 426
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 426
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POC DIAGNOSTICS MARKET 426
15.3 REVENUE ANALYSIS, 2023–2025 428
15.4 MARKET SHARE ANALYSIS, 2025 429
15.5 COMPANY VALUATION AND FINANCIAL METRICS 431
15.6 BRAND/PRODUCT COMPARISON 432
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 433
15.7.1 STARS 433
15.7.2 EMERGING LEADERS 433
15.7.3 PERVASIVE PLAYERS 433
15.7.4 PARTICIPANTS 433
15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025 435
15.7.5.1 Company footprint 435
15.7.5.2 Region footprint 436
15.7.5.3 Mode of purchase footprint 437
15.7.5.4 Technology footprint 438
15.7.5.5 Sample footprint 439
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 440
15.8.1 PROGRESSIVE COMPANIES 440
15.8.2 RESPONSIVE COMPANIES 440
15.8.3 DYNAMIC COMPANIES 440
15.8.4 STARTING BLOCKS 440
15.8.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 442
15.8.5.1 Detailed list of key startups/SMEs 442
15.8.5.2 Competitive benchmarking of startups/SMEs 443
15.9 COMPETITIVE SCENARIO 444
15.9.1 PRODUCT LAUNCHES AND APPROVALS 444
16 COMPANY PROFILES 445
16.1 KEY PLAYERS 445
16.1.1 ABBOTT 445
16.1.1.1 Business overview 445
16.1.1.2 Products offered 446
16.1.1.3 Recent developments 449
16.1.1.3.1 Product launches and approvals 449
16.1.1.3.2 Deals 449
16.1.1.4 MnM view 450
16.1.1.4.1 Right to win 450
16.1.1.4.2 Strategic choices 450
16.1.1.4.3 Weaknesses and competitive threats 450
16.1.2 F. HOFFMANN-LA ROCHE LTD 451
16.1.2.1 Business overview 451
16.1.2.2 Products offered 452
16.1.2.3 Recent developments 454
16.1.2.3.1 Product launches and approvals 454
16.1.2.3.2 Deals 455
16.1.2.3.3 Expansions 455
16.1.2.4 MnM view 456
16.1.2.4.1 Right to win 456
16.1.2.4.2 Strategic choices 456
16.1.2.4.3 Weaknesses and competitive threats 456
16.1.3 SIEMENS HEALTHINEERS AG 457
16.1.3.1 Business overview 457
16.1.3.2 Products offered 458
16.1.3.3 Recent developments 460
16.1.3.3.1 Product launches and approvals 460
16.1.3.3.2 Deals 460
16.1.3.3.3 Expansions 461
16.1.3.4 MnM view 462
16.1.3.4.1 Right to win 462
16.1.3.4.2 Strategic choices 462
16.1.3.4.3 Weaknesses and competitive threats 462
16.1.4 QUIDELORTHO CORPORATION 463
16.1.4.1 Business overview 463
16.1.4.2 Products offered 464
16.1.4.3 Recent developments 466
16.1.4.3.1 Product launches and approvals 466
16.1.4.3.2 Deals 467
16.1.4.3.3 Expansions 467
16.1.4.4 MnM view 467
16.1.4.4.1 Right to win 467
16.1.4.4.2 Strategic choices 468
16.1.4.4.3 Weaknesses and competitive threats 468
16.1.5 DANAHER 469
16.1.5.1 Business overview 469
16.1.5.2 Products offered 470
16.1.5.3 Recent developments 472
16.1.5.3.1 Product launches and approvals 472
16.1.5.3.2 Deals 472
16.1.5.3.3 Expansions 473
16.1.5.4 MnM view 473
16.1.5.4.1 Right to win 473
16.1.5.4.2 Strategic choices 473
16.1.5.4.3 Weaknesses and competitive threats 473
16.1.6 WERFEN 474
16.1.6.1 Business overview 474
16.1.6.2 Products offered 475
16.1.6.3 Recent developments 476
16.1.6.3.1 Product launches and approvals 476
16.1.6.3.2 Deals 476
16.1.6.3.3 Expansions 477
16.1.6.4 MnM view 477
16.1.6.4.1 Right to win 477
16.1.6.4.2 Strategic choices 477
16.1.6.4.3 Weaknesses and competitive threats 477
16.1.7 BD 478
16.1.7.1 Business overview 478
16.1.7.2 Products offered 479
16.1.7.3 Recent developments 480
16.1.7.3.1 Product launches and approvals 480
16.1.7.3.2 Deals 480
16.1.7.3.3 Expansions 481
16.1.8 THERMO FISHER SCIENTIFIC INC. 482
16.1.8.1 Business overview 482
16.1.8.2 Products offered 484
16.1.8.3 Recent developments 484
16.1.8.3.1 Deals 484
16.1.9 BIOMÉRIEUX 485
16.1.9.1 Business overview 485
16.1.9.2 Products offered 486
16.1.9.3 Recent developments 487
16.1.9.3.1 Product launches and approvals 487
16.1.9.3.2 Deals 488
16.1.10 EKF DIAGNOSTICS HOLDINGS PLC 489
16.1.10.1 Business overview 489
16.1.10.2 Products offered 490
16.1.10.3 Recent developments 491
16.1.10.3.1 Product launches and approvals 491
16.1.10.3.2 Expansions 491
16.1.10.3.3 Other developments 492
16.1.11 TRINITY BIOTECH 493
16.1.11.1 Business overview 493
16.1.11.2 Products offered 494
16.1.11.3 Recent developments 495
16.1.11.3.1 Product launches and approvals 495
16.1.11.3.2 Deals 495
16.1.12 ORASURE TECHNOLOGIES, INC. 496
16.1.12.1 Business overview 496
16.1.12.2 Products offered 497
16.1.12.3 Recent developments 498
16.1.12.3.1 Product launches and approvals 498
16.1.12.3.2 Deals 499
16.1.13 GRIFOLS S.A. 500
16.1.13.1 Business overview 500
16.1.13.2 Products offered 501
16.1.13.3 Recent developments 502
16.1.13.3.1 Product launches and approvals 502
16.1.14 QIAGEN 503
16.1.14.1 Business overview 503
16.1.14.2 Products offered 504
16.1.14.3 Recent developments 505
16.1.14.3.1 Product launches and approvals 505
16.1.14.3.2 Deals 506
16.1.14.3.3 Expansions 506
16.2 OTHER PLAYERS 507
16.2.1 NOVA BIOMEDICAL 507
16.2.1.1 Business overview 507
16.2.1.2 Products offered 507
16.2.1.3 Recent developments 508
16.2.1.3.1 Product launches and approvals 508
16.2.1.3.2 Deals 509
16.2.2 SEKISUI DIAGNOSTICS 510
16.2.2.1 Business overview 510
16.2.2.2 Products offered 510
16.2.2.3 Recent developments 511
16.2.2.3.1 Product launches and approvals 511
16.2.3 SEKISUI DIAGNOSTICS 512
16.2.3.1 Business overview 512
16.2.3.2 Products offered 512
16.2.3.3 Recent developments 513
16.2.3.3.1 Product launches and approvals 513
16.2.4 LIFESCAN IP HOLDINGS, LLC 514
16.2.5 PTS DIAGNOSTICS 515
16.2.6 EUROLYSER DIAGNOSTICA GMBH 516
16.2.7 RESPONSE BIOMEDICAL 517
16.2.8 ALFA SCIENTIFIC DESIGNS, INC. 518
16.2.9 BTNX INC. 519
16.2.10 ASCENSIA DIABETES CARE HOLDINGS AG 520
16.2.11 FLUXERGY 521
16.2.12 PRECISION BIOSENSOR, INC. 522
16.2.13 ACON LABORATORIES, INC. 523
16.2.14 MENARINI DIAGNOSTICS S.R.L 524
16.2.15 MANKIND PHARMA 525
17 RESEARCH METHODOLOGY 526
17.1 RESEARCH DATA 526
17.2 RESEARCH APPROACH 526
17.2.1 SECONDARY RESEARCH 527
17.2.1.1 Key data from secondary sources 527
17.2.2 PRIMARY DATA 528
17.2.2.1 Primary sources 529
17.2.2.2 Key data from primary sources 530
17.2.2.3 Key industry insights 531
17.3 MARKET SIZE ESTIMATION 532
17.3.1 BOTTOM-UP APPROACH 533
17.3.1.1 Approach 1: Company revenue estimation approach 533
17.3.1.2 Approach 2: Presentations of companies and primary interviews 534
17.3.1.3 Growth forecast 534
17.3.2 TOP-DOWN APPROACH 535
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 536
17.5 MARKET SHARE ANALYSIS 537
17.6 RESEARCH ASSUMPTIONS 537
17.6.1 PARAMETRIC ASSUMPTIONS 537
17.6.2 GROWTH RATE ASSUMPTIONS 538
17.7 RESEARCH LIMITATIONS 538
17.8 RISK ASSESSMENT 538
18 APPENDIX 539
18.1 DISCUSSION GUIDE 539
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 544
18.3 CUSTOMIZATION OPTIONS 546
18.4 RELATED REPORTS 546
18.5 AUTHOR DETAILS 547